Literature DB >> 14527022

Competitive binding of Pu and Am with bone mineral and novel chelating agents.

R A Guilmette1, R Hakimi, P W Durbin, J Xu, K N Raymond.   

Abstract

Effective direct removal of actinides such as Pu and Am from bone in vivo has not been accomplished to date, even with the strong chelating agents CaNa3DTPA or ZnNa3DTPA. This study, using an established in vitro system, compared removal of Pu and Am bound to bone mineral by ZnNa3DTPA and 10 chelating agents designed specifically to sequester actinides, including Pu and Am. Ligands tested were tetra, hexa, and octadentate, with linear or branched backbones containing sulfocatechol [CAM(S)], hydroxycatechol [CAM(C)], hydroxipyridinone (1,2-HOPO, Me-3,2-HOPO), or hydroxamate functional groups. The wide range of Pu and Am removal exhibited by the test ligands generally agreed with their metal coordination and chemical properties. The most effective agents for Pu (100 microM concentration, 24-48 h contact) are all octadentate as follows: 3,4,3-LICAM(S) (54% unbound); 3,4,3-LICAM(C) (6.2%); 3,4,3-LI(1,2-HOPO) (3.8%); H(2,2)-(Me-3,2-HOPO) (2.2%) and DFO-(1,2-HOPO) (1.8%). The other ligands removed less than 1% of the bound Pu; and ZnNa3DTPA removed only 0.086%. The most effective ligands for Am removal (100 microM, 24-48 h contact) are as follows: octadentate H(2,2)-(Me-3,2-HOPO) (21% unbound); 3,4,3-LI(1,2-HOPO) (14.5%) and 3,4,3-LICAM(C) (5.9%); hexadentate TREN-(Me-3,2-HOPO) and TREN-(1,2-HOPO) (9.6%); and tetradentate 5-LIO(Me-3,2-HOPO) (5.2%). Am removal by ZnNa3DTPA was about 1.4%. Among the ligands presently considered for possible human use, only 3,4,3-LI(1,2-HOPO) removed potentially useful amounts of both Pu and Am from bone mineral.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527022     DOI: 10.1093/oxfordjournals.rpd.a006297

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  3 in total

1.  Molecular dynamics simulations of plutonium binding and its decorporation from the binding-cleft of human serum transferrin.

Authors:  Lokpati Mishra; Mahesh Sundararajan; Tusar Bandyopadhyay
Journal:  J Biol Inorg Chem       Date:  2020-01-24       Impact factor: 3.358

2.  Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake.

Authors:  Olivier Grémy; Nicolas Blanchin; Laurent Miccoli
Journal:  Health Phys       Date:  2021-11-01       Impact factor: 1.316

3.  Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats.

Authors:  Janina Boyken; Thomas Frenzel; Jessica Lohrke; Gregor Jost; Gunnar Schütz; Hubertus Pietsch
Journal:  Invest Radiol       Date:  2019-02       Impact factor: 6.016

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.